LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 11 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 1. - Dataset (ID:20248)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Hs 578T | CGP60474 | 1.11 | uM | LJP5 | 72 | hr | 929 | 837 | 3237 | 0.2587 | -0.0567 |
| SK-BR-3 | Barasertib | 10 | uM | LJP5 | 72 | hr | 1476 | 1365 | 3772 | 0.3621 | -0.0563 |
| MDA-MB-231 | SNS-032 | 0.37 | uM | LJP6 | 72 | hr | 868 | 771 | 3556 | 0.2172 | -0.0562 |
| MCF7 | GDC-0980 | 0.37 | uM | LJP5 | 72 | hr | 1235 | 1114 | 4267 | 0.2615 | -0.0560 |
| BT-20 | AZD8055 | 10 | uM | LJP6 | 72 | hr | 1657 | 1508 | 5383 | 0.2798 | -0.0557 |
| Hs 578T | WZ3105 | 3.33 | uM | LJP5 | 72 | hr | 929 | 839 | 3237 | 0.2592 | -0.0552 |
| MCF 10A | Mitoxantrone | 10 | uM | LJP5 | 72 | hr | 513 | 403 | 10362 | 0.0389 | -0.0545 |
| Hs 578T | Withaferin A | 1.11 | uM | LJP5 | 72 | hr | 929 | 840 | 3237 | 0.2596 | -0.0544 |
| MDA-MB-231 | GSK1059615 | 3.33 | uM | LJP5 | 72 | hr | 868 | 781 | 3410 | 0.2288 | -0.0542 |
| MDA-MB-231 | Dasatinib | 0.04 | uM | LJP6 | 72 | hr | 868 | 777 | 3556 | 0.2184 | -0.0539 |
| MCF 10A | SNS-032 | 10 | uM | LJP6 | 72 | hr | 513 | 407 | 10473 | 0.0389 | -0.0534 |
| BT-20 | Radicicol | 10 | uM | LJP5 | 72 | hr | 1657 | 1506 | 5588 | 0.2697 | -0.0531 |
| BT-20 | BI-2536 | 0.12 | uM | LJP6 | 72 | hr | 1657 | 1511 | 5383 | 0.2810 | -0.0529 |
| MCF 10A | Mitoxantrone | 3.33 | uM | LJP6 | 72 | hr | 513 | 407 | 10473 | 0.0389 | -0.0529 |
| MCF7 | Alvocidib | 0.04 | uM | LJP6 | 72 | hr | 1235 | 1126 | 4056 | 0.2776 | -0.0528 |
| MCF7 | Dasatinib | 0.04 | uM | LJP6 | 72 | hr | 1235 | 1127 | 4056 | 0.2781 | -0.0520 |
| MDA-MB-231 | SNS-032 | 10 | uM | LJP6 | 72 | hr | 868 | 782 | 3556 | 0.2196 | -0.0517 |
| SK-BR-3 | AZD 5438 | 1.11 | uM | LJP6 | 72 | hr | 1476 | 1387 | 3643 | 0.3798 | -0.0516 |
| SK-BR-3 | Neratinib | 0.12 | uM | LJP5 | 72 | hr | 1476 | 1374 | 3772 | 0.3644 | -0.0516 |
| Hs 578T | GW843682X | 3.33 | uM | LJP6 | 72 | hr | 929 | 847 | 3216 | 0.2634 | -0.0509 |
| SK-BR-3 | Foretinib | 1.11 | uM | LJP5 | 72 | hr | 1476 | 1376 | 3772 | 0.3650 | -0.0507 |
| BT-20 | JNK-9L | 3.33 | uM | LJP6 | 72 | hr | 1657 | 1519 | 5383 | 0.2821 | -0.0506 |
| MCF 10A | Dasatinib | 1.11 | uM | LJP6 | 72 | hr | 513 | 410 | 10473 | 0.0392 | -0.0505 |
| MCF7 | QL-XII-47 | 0.37 | uM | LJP6 | 72 | hr | 1235 | 1131 | 4056 | 0.2790 | -0.0499 |
| BT-20 | CGP60474 | 1.11 | uM | LJP5 | 72 | hr | 1657 | 1516 | 5588 | 0.2713 | -0.0497 |